44 results about "Aromatic hydrocarbon receptor" patented technology

The present invention relates to methods, kits and compositions for expansion of hematopoietic stem / progenitor cells and providing hematopoietic function to human patients in need thereof. In one aspect, it relates to kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. Also provided herein are methods for expanding the hematopoietic stem / progenitor cells using kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. The hematopoietic stem / progenitor cells expanded using the disclosed kits, compositions and methods include human umbilical cord blood stem / progenitor cells, placental cord blood stem / progenitor cells and peripheral blood stem cells. The present invention also relates to administering hematopoietic stem / progenitor cells expanded using a combination of a Notch agonist and an aryl hydrocarbon receptor antagonist to a patient for short-term and / or long-term in vivo repopulation benefits.

The present invention relates to compounds, compositions, and methods for brightening skin. The compounds, compositions, and methods of the present invention generally involve compounds produced by a Malassezia yeast, and chemical analogs thereof. In addition to skin brightening applications, the compounds, compositions, and methods of the present invention may be used to modulate melanocyte activity, induce melanocyte apoptosis, agonize an arylhydrocarbon receptor (AhR), improve hyperpigmentation caused by a hyperpigmentation disorder, and modulate melanin production, melanosome biogenesis, and melanosome transfer.

The present invention relates to a method of screening compounds for binding to hsp90 by exposing a compound to hsp90 or a polypeptide fragment thereof containing amino acid residues 538-728 of the full length protein and determining whether the compound binds to hsp90 of the polypeptide fragment thereof. Also disclosed is a method of screening compounds for inhibition of hsp90 activity. The present invention further relates to a method of screening compounds as a cancer therapeutic and a method of treating cancerous conditions. Also disclosed is a method of inhibiting transcription-inducing activity of an aryl hydrocarbon receptor in a cell and a method of modifying expression of a gene that is activated by an aryl hydrocarbon receptor.

The invention discloses an aromatic hydrocarbon receptor modulator shown in a formula (I) and a pharmaceutically acceptable salt thereof. The formula (I) is described in the specification, wherein R'is H, CN, CH2(OH)RO, CmH2m+1, CnH2n-1, CnH2n-3 or two groups (described in the specification), and two Ra groups are independently H or jointly form =O or =N-W3-R1; A is a C6-C10 aromatic ring unsubstituted or with 1-3 R substituted, a C2-C10 heteroaromatic ring mixed with 1-5 heteroatoms selected from N, O and S or a quaternary to heptatomic nonaromatic heterocyclic ring which is mixed with 1-3 heteroatoms selected from N, O and S and contains C=N; Q is R, or a C6-C10 aromatic ring unsubstituted or with 1-3 R substituted, or a C2-C10 heteroaromatic ring mixed with 1-5 heteroatoms selected from N, O and S; and R is RC connected with C or RN connected with N. The compound shown in a formula (I) can regulate AhR activity and can be used for inhibiting cancer cell growth as well as migrationand invasion of tumor cells.

The invention relates to a recombinant vector and a recombinant cell, in particular to a humanized recombinant vector and recombinant cell for detecting aromatic hydrocarbon receptor ligands (such as dioxin-type substances). The invention also relates to a purpose of the recombinant vector and cell in the aspects of biological detection of aromatic hydrocarbon receptor ligands (such as dioxin-type substances). The DRE-sequence-containing human CYP1A1 gene promoters or partial segments of the promoters are cloned to a basic genetic vector with a luciferase recording gene, the obtained recombinant vector and cell have good response on the dioxin; the lowest detection limit can reach 0.3pM; the humanized recombinant vector and cell are particularly suitable for elevating the influence of the aromatic hydrocarbon receptor ligands (such as dioxin-type substances) on the human body health and performing relevant mechanism study.

The purpose of the present invention is to provide a probiotic(s) which can activate an aromatic hydrocarbon receptor (AhR) and can consequently prevent inflammatory damage in the digestive tract. The present invention relates to; a probiotic(s) capable of activating an AhR; an anti-inflammatory agent comprising the probiotic(s); an orally ingestible composition containing the anti-inflammatory agent; and a method for screening for the probiotic(s).

The invention in the technical field of skin care product composition preparation discloses a preparation method of a skin care product composition containing camellia extract. The skin care product composition containing camellia extract comprises: 0.5-2 parts of RedSnow, 1 part of hydrogenated lecithin, 2 parts of methylpropylene glycol, and 1 part of Prosix EPI. Prosix EPI is used to maintain the natural barrier of skin and increase the content of NMF in the skin, methylpropylene glycol is used as a solvent to disperse RedSnow, lecithin is used as an outer phospholipid membrane lipid which emulsifies and wraps a transdermal short peptide and green algae extract to protect the effective transmission of the complex. According to the present invention, the paths of the skin problems caused by environmental pollution of aromatic hydrocarbon receptor (AhR), oxidase NADPH-oxidase 1 (NOX-1), c-Fos, and oxygenase COX-2 can be inhibited so as to improve the skin barrier function, the skin care product composition can be applied as an additive with skin repairing efficacy to mask essence liquid, essence liquid, emulsion and cream in skin care products, and the safety and stability of the product is ensured.

The disclosure relates to aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as methods of modulating aryl hydrocarbon receptor activity and treating various pathologies, such as cancer, by adminstation of these aryl hydrocarbon receptor antagonists. Additionally, the disclosure provides methods of synthesizing aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as compositions and kits containing aryl hydrocarbon receptor antagonists that can be used for the treatment of diseases and disorders.

Provided herein are methods of cancer treatment by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its structural analogs to a patient with cancer, for example, prostate, liver, lung, ovarian, breast, skin, colon (or rectum), stomach, pancreatic, kidney, bladder, soft tissue, or cervical cancer.

Uses of ethyl 5,11-dihydroindolo[3,2-b]carbazole-6-carboxylate as a fluorescent ligand probe, preferably in a binding assay for quantitative analysis in combination with a recombinant aryl hydrocarbon receptor (AhR) protein. A method for detection or quantitative analysis of suspected aryl hydrocarbon receptor (AhR) ligands in a sample, the method comprising the steps of: (a) providing a sample possibly containing at least one known or unknown AhR ligand; (b) mixing said sample with a composition comprising a recombinant AhR protein bound to ethyl 5,11-dihydroindolo[3,2-b]carbazole-6-carboxylate; and (c) determining the presence or the total amount of said at least one known or unknown AhR ligand in the sample by fluorescence spectroscopy. Use e.g. for screening of unknown compounds to determine their binding ability to AhR; for analyzing unknown chemical mixtures to assess the presence of ligands able to bind to AhR; for screening of Polycyclic Aromatic Hydrocarbon (PAHs) from water, food or sediment; for screening of PAHs or dioxin-like compounds in water, food or sediment; for testing for pollutant removal in water and waste water treatment plants; for testing for water reuse; for testing the presence of dioxin-like compounds in incinerator plants; or for testing of bodily fluids of humans or animals exposed to PAHs or dioxin-like compounds.

The present invention provides a new application of aryl hydrocarbon receptor (AhR) in predicting the effect of immunotherapy, specifically, the present invention provides the application of AhR as a target in the development, screening and / or preparation of drugs for treating tumors , also provides the application of the reagents for inhibiting, silencing and / or knocking out AhR in the preparation of drugs for treating tumors, and also provides the use of reagents for detecting the level of AhR in the preparation for predicting the effect of immune checkpoint inhibitors in treating tumors application in agents.

The invention discloses a compound 5-(4-hydroxyl-3-methoxyl benzylidene)-2-(2-nitryl phenylimino) thiazolidone, HMNT for short, and an application thereof in an aromatic hydrocarbon receptor stimulant, wherein the chemical structure is as shown in a formula (I). Experiments verify that the compound disclosed by the invention effectively causes up-regulation of genetic expression and protein expression of a metabolic enzyme CYP1A1 of a related allogenic material of a downstream target gene of an aromatic hydrocarbon receptor in a mouse hepatoma carcinoma cell at the concentration of 10 mu M and prompts that the compound is the aromatic hydrocarbon receptor stimulant, is expected to become a potential drug by taking the aromatic hydrocarbon receptor as a tumor treating target, and is wide in clinical application prospect.

The present invention provides a highly functional platelet production promoting agent which comprises one or a plurality of aryl hydrocarbon receptor (AhR) antagonists and one or a plurality of Rho-associated coiled-coil forming kinase (ROCK) inhibitors.

A previously unknown T cell receptor (TCR) activation pathway dependent on the aryl hydrocarbon receptor conferring resistance to calcineurin inhibitors and mTOR inhibitors is disclosed, including application of this pathway to the diagnosis and treatment of certain disease states refractory to treatment with calcineurin inhibitors. This alternative TCR activation pathway uniquely exists in a subset of CD8 T cells expanded in the setting of chronic rejection or rheumatoid arthritis. Expansion of this newly discovered calcineurin and mTOR inhibitor resistant CD8 T cell subset in humans can be quantified by measuring levels of certain biomarkers in the circulating CD8 T cell pool, such as Pla2g4a, to diagnose disease states mediated thereby. Additionally, methods for diagnosing ongoing active inflammation mediated by this resistant CD8 T cell subset in either chronic rejection or rheumatoid arthritis are provided, which comprise measuring levels of the biomarker Scin in the circulating CD8 T cell pool.